Acetazolamide Trial in Normal Pressure Hydrocephalus

Who can take part

• Diagnosis of idiopathic normal pressure hydrocephalus according to international guidelines
• Age ≥ 50 years and ≤ 82 years
• Cognitive function with Mini-Mental State Examination > 20 points or cognitive domain of iNPH scale ≥ 30 points
• MRI image characteristic of normal pressure hydrocephalus, defined as callosal angle < 90 degrees and dilated lateral ventricles or pattern of disproportionately enlarged subarachnoid space hydrocephalus (DESH)
• Signed informed consent form

Who cannot take part

• Treatment with phenytoin, valproate, carbamazepine, lithium, oral anticoagulants, thiazide-diuretics, or acetylsalicylic acid > 100 mg/day
• Inability to comply with the study treatment independently, and a concurrent lack of individuals to help the patient comply with the treatment during the study period
• Other disease likely to impact the symptoms of the patient
• Known heart failure
• Allergy to acetazolamide, sulfonamides, or sulfonamide derivatives
• Reduced kidney function with GFR < 50
• Reduced liver function (increased INR or alanine transaminase concentrations in plasma elevated more than 1.5 times reference values)
• Exclusion criteria for MRI examination
• Participation in another medical trial
• Wheelchair user or unable to walk without support
• Low concentrations of electrolytes in blood plasma that, according to the investigator, prevents participation in the study
• Angle-closure glaucoma
• Inability to swallow capsules of the same size as the investigational medicinal products (will be tested using empty capsules when the patient is asked to participate in the study)
• Average walking time for the three walking tests < 10.5 seconds for men and < 11.5 seconds for women
• Average walking time for the three walking tests > 50 seconds
• Fertile woman without highly effective contraception. A Fertile woman will be tested with pregnancy test before inclusion is possible